Viatris

Yahoo Finance • 9 days ago

Viatris Outlines Long-term Financial Targets

(RTTNews) - Viatris (VTRS) said, for combined long-term Targets through 2030, the company expects to deliver 5% to 6% total revenues CAGR, 7% to 8% adjusted EBITDA CAGR, 9% to 10% adjusted EPS CAGR and more than $3 billion in annual free c... Full story

Yahoo Finance • 10 days ago

1 Cash-Producing Stock to Target This Week and 2 That Underwhelm

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. Not all companies are created equal, a... Full story

Yahoo Finance • 11 days ago

ISCV vs. VBR: Which Small Cap Value Approach is Right for Investors?

The Vanguard Small-Cap Value ETF (NYSEMKT:VBR) and iShares Morningstar Small-Cap Value ETF(NYSEMKT:ISCV) both target U.S. small-cap value stocks, but ISCV offers a marginally higher yield, heavier exposure to financial services, and much s... Full story

Yahoo Finance • 12 days ago

What Are Analysts Saying About Viatris Inc (VTRS) Stock?

Viatris Inc. (NASDAQ:VTRS) is one of the 13 extreme value stocks to buy now. Viatris Inc. (NASDAQ:VTRS) is covered by 12 analysts on Wall Street with a medium price target of $16, suggesting 12.36% upside from current levels. On February 2... Full story

Yahoo Finance • 15 days ago

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

Key Points Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million. Meanwhile, the quarter-end position value rose by $99.77 million, reflecting both the new... Full story

Yahoo Finance • 15 days ago

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline

On February 17, 2026, Deerfield Management Company disclosed a buy of Praxis Precision Medicines(NASDAQ:PRAX), adding 62,500 shares in a trade estimated at $11.64 million based on quarterly average pricing. What happened According to a f... Full story

Yahoo Finance • 15 days ago

Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index down 1.3% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 15 days ago

Sector Update: Health Care Stocks Lower in Afternoon Trading

Health care stocks declined Thursday afternoon, with the NYSE Health Care Index and the State Street PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 17 days ago

Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings?

Viatris has had an impressive run over the past six months as its shares have beaten the S&P 500 by 34.7%. The stock now trades at $14.11, marking a 37.8% gain. This was partly due to its solid quarterly results, and the performance may ha... Full story

Yahoo Finance • 25 days ago

Theravance drops rare disease drug after late-stage trial setback

[Red arrow And dollar finance decline graph- Stock image] Baris-Ozer Theravance Biopharma (TBPH [https://seekingalpha.com/symbol/TBPH]) announced on Tuesday that it will halt its clinical program for its rare disease therapy ampreloxetine... Full story

Yahoo Finance • 25 days ago

Viatris (VTRS) Delivers Solid 2025 Growth and Robust Cash Flow at Deep Value

Viatris Inc. (NASDAQ:VTRS) is one of the dirt cheap stocks to buy now. On February 26, Viatris reported a steady financial performance for the full-year 2025, generating $14.3 billion in total revenue, a 2% increase over the previous year... Full story

Yahoo Finance • 27 days ago

Notable healthcare headlines for the week: Viatris, Novo Nordisk, and Gilead Sciences in focus

Wall Street’s major market averages finished lower on Friday after the January wholesale inflation report came in hotter than expected. The blue-chip Dow was last lower by 1%, while the benchmark S&P 500 was -0.4%. At the same time, the t... Full story

Yahoo Finance • 27 days ago

UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve

Viatris Inc. (NASDAQ:VTRS) is included among the 13 Best March Dividend Stocks to Buy.UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve On February 27, UBS raised its price recommendation on Viatris Inc. (N... Full story

Yahoo Finance • last month

UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade

Viatris Inc. (NASDAQ:VTRS) is among the 7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds.UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade The third stock on our list of cheap pharmaceuti... Full story

Yahoo Finance • last month

Glenview Capital's top Q4 moves include closing out PYPL, PINS stakes, boosting LION

[investor reviewing stock reports and financial dashboards on hybrid tablet-laptop with AI digital finance workflow with business charts and online investment platforms] primeimages Glenview Capital dumped its holdings in PayPal Holdings... Full story

Yahoo Finance • 3 months ago

VBR Offers Greater Size While ISCV Pays Higher Yield

Key Points VBR is much larger and more liquid than ISCV, but comes with a slightly higher expense ratio. ISCV holds more stocks, while VBR has delivered stronger five-year growth. Both ETFs tilt toward small-cap value stocks, but sector w... Full story

Yahoo Finance • 3 months ago

Viatris Says FDA Approves Octreotide Acetate, Clears MR-146 for Clinical Trials

Viatris (VTRS) said Thursday the US Food and Drug Administration approved octreotide acetate for inj PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

FDA Approves Viatris' Generic Sandostatin LAR Depot; To Review Weekly Contraceptive Patch Next July

(RTTNews) - Viatris Inc. (VTRS), a healthcare company, Thursday announced updates on its four regulatory milestones spanning across all stages of its global pipeline. -- The FDA has approved the company's octreotide acetate for injectable... Full story

Yahoo Finance • 3 months ago

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

PITTSBURGH, Dec. 17, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13, 20... Full story

Yahoo Finance • 3 months ago

Notable healthcare headlines for the week: CVS, Eli Lilly and Novartis in focus

Wall Street's major averages ended lower on Friday, with the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) and the Nasdaq (COMP:IND [https://seekingalpha.com/symbol/COMP:IND]) ending the week in the red as the AI trade came under... Full story